HK1134508A1 - Antibodies against c5 inhibiting type ii endothelial cell activation ii c5 - Google Patents
Antibodies against c5 inhibiting type ii endothelial cell activation ii c5Info
- Publication number
- HK1134508A1 HK1134508A1 HK10102519.6A HK10102519A HK1134508A1 HK 1134508 A1 HK1134508 A1 HK 1134508A1 HK 10102519 A HK10102519 A HK 10102519A HK 1134508 A1 HK1134508 A1 HK 1134508A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- endothelial cell
- cell activation
- inhibitors
- antibodies against
- inhibiting type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23930900P | 2000-10-10 | 2000-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1134508A1 true HK1134508A1 (en) | 2010-04-30 |
Family
ID=22901599
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10102519.6A HK1134508A1 (en) | 2000-10-10 | 2010-03-10 | Antibodies against c5 inhibiting type ii endothelial cell activation ii c5 |
HK15111863.4A HK1211043A1 (en) | 2000-10-10 | 2015-12-02 | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5 |
HK16113934A HK1225741A1 (zh) | 2000-10-10 | 2016-12-07 | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111863.4A HK1211043A1 (en) | 2000-10-10 | 2015-12-02 | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5 |
HK16113934A HK1225741A1 (zh) | 2000-10-10 | 2016-12-07 | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6534058B2 (de) |
EP (5) | EP1325033B1 (de) |
AT (1) | ATE449791T1 (de) |
AU (1) | AU2001296594A1 (de) |
CA (1) | CA2424379C (de) |
DE (1) | DE60140618D1 (de) |
DK (1) | DK1325033T3 (de) |
ES (2) | ES2483991T3 (de) |
HK (3) | HK1134508A1 (de) |
PT (1) | PT1325033E (de) |
WO (1) | WO2002030985A2 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021527A1 (it) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
WO2004050111A2 (en) * | 2002-12-02 | 2004-06-17 | Resistentia Pharmaceuticals Ab | Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
US20070123466A1 (en) * | 2003-05-13 | 2007-05-31 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of treating recurrent miscarriages |
ATE498010T1 (de) * | 2004-03-01 | 2011-02-15 | Immune Disease Inst Inc | Natürliche igm-antikörper und inhibitoren davon |
EP2338511A3 (de) | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Verlängerung der Überlebungszeit eines Allografts durch Hemmung der Komplementsaktivität |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
AU2013200223B2 (en) * | 2005-11-04 | 2015-08-20 | Genentech, Inc. | Use of Complement Pathway Inhibitors to Treat Ocular Diseases |
JP2009514888A (ja) * | 2005-11-04 | 2009-04-09 | ジェネンテック・インコーポレーテッド | 眼疾患を処置するための補体経路の阻害剤の使用 |
EP1988882B1 (de) * | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Verlängerte lebensdauer eines allotransplantats mittels hemmung von komplementaktvität |
EP3167888B1 (de) | 2006-03-15 | 2024-05-01 | Alexion Pharmaceuticals, Inc. | Behandlung von patienten mit paroxysmaler nächtlicher hämoglobinurie mit einem komplementinhibitor |
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
CA2662480C (en) | 2006-09-05 | 2016-11-08 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
TW201534620A (zh) * | 2006-11-02 | 2015-09-16 | Genentech Inc | 人類化之抗-因子d抗體及其用途 |
PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
DK2275443T3 (en) | 2008-04-11 | 2016-02-08 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repetitively binding to two or more antigen molecules |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
AU2014201433B2 (en) * | 2008-08-05 | 2016-05-26 | Novartis Ag | Compositions and methods for antibodies targeting complement protein C5 |
CN102170906B (zh) * | 2008-08-05 | 2014-07-30 | 诺华股份有限公司 | 靶定补体蛋白c5的抗体的组合物和方法 |
TR201910848T4 (tr) | 2009-02-13 | 2019-08-21 | Immunomedics Inc | İntraselüler olarak ayrilabi̇len bi̇r bağa sahi̇p i̇mmunokonjugatlar |
EP2478110B1 (de) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Klasse-i-anti-cea-antikörper und verwendungen davon |
IN2012DN03354A (de) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
CN107115526A (zh) | 2011-05-02 | 2017-09-01 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
EP3330288A1 (de) | 2011-12-21 | 2018-06-06 | Novartis AG | Zusammensetzungen die gegen faktor p gerichtete antikörper enthalten |
US9808502B2 (en) | 2012-02-20 | 2017-11-07 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement C5 |
CN109513003A (zh) | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分c5拮抗劑之篩選分析 |
CN105051057B (zh) | 2012-11-15 | 2019-11-19 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法 |
KR20230078823A (ko) | 2012-12-13 | 2023-06-02 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
BR112015018438A2 (pt) * | 2013-01-31 | 2017-07-18 | Seoul Nat Univ R&Db Foundation | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento |
US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
EA201690213A1 (ru) | 2013-08-12 | 2016-07-29 | Дженентек, Инк. | Композиции и способ лечения связанных с комплементом состояний |
PT3038633T (pt) | 2013-08-28 | 2021-01-14 | Ipc Res Llc | Polipéptidos estáveis que se ligam ao complemento humano c5 |
CN117964710A (zh) | 2013-08-28 | 2024-05-03 | 阿菲博迪公司 | 具有突变的支架的结合多肽 |
MX2016010683A (es) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2. |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
AU2015253042A1 (en) | 2014-05-01 | 2016-10-20 | Genentech, Inc. | Anti-factor D antibody variants and uses thereof |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
WO2016057398A1 (en) | 2014-10-07 | 2016-04-14 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
SG10201710322VA (en) | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
EP3247723A1 (de) | 2015-01-22 | 2017-11-29 | Chugai Seiyaku Kabushiki Kaisha | Kombination von zwei oder mehr anti-c5-antikörpern und verfahren zur verwendung |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
EP3313443B9 (de) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs |
EP3316885B1 (de) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antikörper-sn-38-immunkonjugate mit einem cl2a-linker |
CA3001128A1 (en) | 2015-10-07 | 2017-04-13 | Apellis Pharmaceuticals, Inc. | Use of long-acting compstatin analog for treating a complement-mediated eye disorder |
TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
WO2017075252A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody variant conjugates and uses thereof |
EP3368074A2 (de) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-faktor-d-antikörper und -konjugate |
JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗c5抗体及びそれらの使用 |
IL264626B (en) | 2016-08-05 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | A preparation for the prevention or treatment of diseases related to il-8 |
MY201148A (en) | 2017-01-31 | 2024-02-07 | Hoffmann La Roche | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
CA3059304A1 (en) | 2017-04-07 | 2018-10-11 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
US20210301004A1 (en) | 2018-08-01 | 2021-09-30 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
WO2021019036A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
AU2020319677A1 (en) | 2019-07-31 | 2022-01-06 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab |
WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
CN111171149B (zh) * | 2020-02-23 | 2021-09-07 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c5分子的人源化单链抗体及其应用 |
EP4150338A1 (de) | 2020-05-15 | 2023-03-22 | Alexion Pharmaceuticals, Inc. | Verfahren zur verwendung von extrazellulären vesikeln zur erkennung von komplementaktivierungen und verwendungen davon zur beurteilung und/oder überwachung der behandlung einer komplementvermittelten erkrankung |
CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
EP4342497A1 (de) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antikörper mit reduzierter bindungsaffinität für antigen |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5506247A (en) | 1988-04-15 | 1996-04-09 | T Cell Sciences, Inc. | Compounds that inhibit complement and/or suppress immune activity |
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
EP0751787B1 (de) * | 1994-03-23 | 2005-01-12 | Alexion Pharmaceuticals, Inc. | Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679345A (en) | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
US5546808A (en) | 1994-09-06 | 1996-08-20 | Harris Instrument Corporation | Apparatus and method for binocular measurement system |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
CA2248772C (en) | 1996-03-13 | 2007-06-12 | John D. Lambris | Novel peptides which inhibit complement activation |
AU7466998A (en) | 1997-04-14 | 1998-11-11 | Byron E. Anderson | Method and material for inhibiting complement |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
-
2001
- 2001-10-04 DK DK01977478.5T patent/DK1325033T3/da active
- 2001-10-04 AU AU2001296594A patent/AU2001296594A1/en not_active Abandoned
- 2001-10-04 CA CA2424379A patent/CA2424379C/en not_active Expired - Lifetime
- 2001-10-04 EP EP01977478A patent/EP1325033B1/de not_active Expired - Lifetime
- 2001-10-04 US US09/682,672 patent/US6534058B2/en not_active Expired - Lifetime
- 2001-10-04 ES ES09167955.5T patent/ES2483991T3/es not_active Expired - Lifetime
- 2001-10-04 DE DE60140618T patent/DE60140618D1/de not_active Expired - Lifetime
- 2001-10-04 ES ES01977478T patent/ES2333775T3/es not_active Expired - Lifetime
- 2001-10-04 EP EP15154800.5A patent/EP2896631A1/de not_active Withdrawn
- 2001-10-04 AT AT01977478T patent/ATE449791T1/de active
- 2001-10-04 EP EP09167955.5A patent/EP2113516B1/de not_active Expired - Lifetime
- 2001-10-04 EP EP10179315A patent/EP2281840A3/de not_active Withdrawn
- 2001-10-04 WO PCT/US2001/031103 patent/WO2002030985A2/en active Application Filing
- 2001-10-04 PT PT01977478T patent/PT1325033E/pt unknown
- 2001-10-04 EP EP16152143.0A patent/EP3031827A1/de not_active Withdrawn
-
2010
- 2010-03-10 HK HK10102519.6A patent/HK1134508A1/xx not_active IP Right Cessation
-
2015
- 2015-12-02 HK HK15111863.4A patent/HK1211043A1/xx unknown
-
2016
- 2016-12-07 HK HK16113934A patent/HK1225741A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2113516A1 (de) | 2009-11-04 |
CA2424379C (en) | 2013-10-01 |
EP3031827A1 (de) | 2016-06-15 |
EP2113516B1 (de) | 2014-05-21 |
AU2001296594A1 (en) | 2002-04-22 |
EP2896631A1 (de) | 2015-07-22 |
HK1211043A1 (en) | 2016-05-13 |
ES2483991T3 (es) | 2014-08-08 |
DE60140618D1 (de) | 2010-01-07 |
EP1325033B1 (de) | 2009-11-25 |
ATE449791T1 (de) | 2009-12-15 |
US20020041875A1 (en) | 2002-04-11 |
WO2002030985A2 (en) | 2002-04-18 |
CA2424379A1 (en) | 2002-04-18 |
EP2281840A2 (de) | 2011-02-09 |
HK1225741A1 (zh) | 2017-09-15 |
WO2002030985A3 (en) | 2002-12-05 |
US6534058B2 (en) | 2003-03-18 |
EP2281840A3 (de) | 2012-05-23 |
DK1325033T3 (da) | 2010-04-06 |
EP1325033A2 (de) | 2003-07-09 |
ES2333775T3 (es) | 2010-03-01 |
PT1325033E (pt) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225741A1 (zh) | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 | |
CY1108663T1 (el) | Αναστολεις της ενεργοποιησης συμπληρωματος | |
WO2001070818A8 (en) | Anti-c2/c2a inhibitors of complement activation | |
NO2006008I2 (no) | Natalizumab, anti alfa-4 integrin humanized monoclonal antibody | |
WO1998057994A3 (en) | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
NZ611387A (en) | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment | |
KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
NZ596723A (en) | Human antibodies that bind human il-12 and methods for producing | |
CA2149120A1 (en) | Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof | |
EP1112085A4 (de) | Anti-thrombotisches agens und humanisierter monoklonaler antikörper gegen von-willebrand faktor | |
WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
WO2003075846A3 (en) | Uses of monoclonal antibody 8h9 | |
EP1546205A4 (de) | Verfahren zur kontrolle von krebs | |
DE69922834D1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
WO2002094194A3 (en) | Compositions and methods for inhibiting metastasis | |
IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same | |
WO2004039401A3 (en) | Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis | |
HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20211003 |